Oxaliplatin-Related Acute Disseminated Intravascular Coagulation Syndrome in a Patient With Metastatic Colon Cancer

Malkhasyan, Karen; Halene, Stephanie; Lacy, Jill

doi:10.1016/j.clcc.2014.09.011

Cited by 7 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several other case reports showing associations between oxaliplatin and hematologic abnormalities such as immune-mediated hemolytic anemia [5,6], ITP [4,5], and thrombotic thrombocytopenic purpura [7]. However, there are only 3 case reports to date suggesting an association between oxaliplatin and DIC, all described in cases of metastatic colon cancer [9,10,11]. …”

Section: Discussionmentioning

confidence: 98%

“…The third case of DIC reported was in a 61-year-old man with diffuse and extensively metastatic colon cancer [10]. On cycle 18 of FOLFOX, bevacizumab was administered, followed by leucovorin with concurrent oxaliplatin.…”

Section: Discussionmentioning

confidence: 99%

“…Rarely, it is known to be implicated in hypersensitivity reactions [4], and is less known to be associated with hematologic abnormalities such as immune-mediated hemolytic anemia [5,6], immune thrombocytopenia (ITP) [4,5], and thrombotic thrombocytopenic purpura [7]. To date, there are few reported cases of disseminated intravascular coagulation (DIC) associated with oxaliplatin administration [8,9,10,11]. In this case report, we describe a 71-year-old man with metastatic colon adenocarcinoma and chronic ITP who presented with an acute hypersensitivity reaction followed by DIC and acute kidney injury (AKI) after the infusion of oxaliplatin.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion

Waddle

Irvin

Gupta³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

Oxaliplatin is one of the most commonly used drugs for patients with colorectal cancer. It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases. In all those instances, the patients had started receiving oxaliplatin, developed evidence of DIC during the course of planned treatment, and recovered with supportive care. We report a case of a 71-year-old man with colorectal cancer treated successfully with an oxaliplatin-based regimen who had disease relapse after 3 years. When treated again with oxaliplatin, he developed signs of an acute hypersensitivity reaction, and eventually had signs and symptoms consistent with DIC despite appropriate management. This case is unique in that a DIC reaction evolving from a hypersensitivity reaction occurred after the patient had already tolerated the drug years earlier. It suggests a possible immune-mediated etiology to this rare occurrence that should be kept in mind while utilizing this commonly employed drug.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion

Waddle

Irvin

Gupta³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…In cases of Evans syndrome or hemolytic anemia associated with oxaliplatin, positive DAT results are reported for IgG or C3 complement proteins (Cobo et al, 2007). Decreased levels of ADAMTS13 were found in oxaliplatin-induced thrombotic thrombocytopenic purpura without specific antibodies to this protein (Baretta et al, 2013;Malkhasyan et al, 2015). Fibrinolysis induced by oxaliplatin may be the underlying mechanism of disseminated intravascular coagulation (DIC) (kurian et al, 2012).…”

Section: Underlying Mechanisms Of Oxaliplatin Induced Hsrmentioning

confidence: 99%

Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches

Bano

Najam²,

Qazi³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Oxaliplatin, a third generation novel platinum compound is the most effective first line chemotherapeutic agent for colorectal cancer (CRC) in combination with 5FU and leucovorin. It is indicated for pancreatic, gastric and testicular cancers combined with bevacuzimab, capecitabine, irinotecan and other cytotoxic agents. However, moderate to severe hypersensitivity reactions (HSR) during or after oxaliplatin infusion usually require cessation of chemotherapy or substitution of the key therapeutic drug which largely interferes with improved patient prognosis. This mini-review showcases recent and accepted opinions/approaches in oxaliplatin induced HSR management. Physicians and oncologists have varying attitudes regarding the decision to rechallenge the patient after an HSR experience, efficacy of desensitization protocols, effectiveness and selection of drugs for premedication and possibilities of cross sensitivity to other platinum agents (e.g. carboplatin). A brief insight into underlying molecular mechanisms and clinical manifestations of oxaliplatin induced HSR is offered. We have also discussed the management of oxaliplatin induced HSR and risk stratification for a successful and complete chemotherapeutic plan.

show abstract

“…Tamoxifen prophylaxis in ER-positive breast cancers results in statistically significantly higher rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) (12). Disseminated intravascular coagulation (DIC) is characteristic for prostate cancer (13) but it can also develop in association with acute hemolysis during oxaliplatin infusion (14).…”

mentioning

confidence: 99%

Studies Towards Hemocompatibility of Polyamine Conjugates With Bicyclic Systems

Szumilak¹,

Markowicz-Piasecka²,

Mikiciuk-Olasik³

et al. 2018

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

Assessing hemocompatibility of anticancer drug candidate is a very important task due to the fact that coagulation disorders are often correlated with malignancy or induced by chemotherapy. The aim of this study was to examine the influence of some polyamine conjugates with bicyclic systems on the process of coagulation and fibrinolysis. In addition, their effect on the healthy human erythrocytes (RBCs) was assessed. Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), clot formation and lysis test (CL-test) were performed to evaluate the influence of some polyamine conjugates on plasma hemostasis. The effects of tested compounds on RBCs were assessed using hemolysis assays and microscopy studies. APTT and PT examinations revealed that all tested compounds apart from the highest concentrations of compounds 3 and 5 did not exert significant effects on intrinsic and extrinsic coagulation pathways. Despite their substantial influence on the kinetic parameters of the process of clot formation and fibrinolysis, the examined compounds, over the entire concentration range, did not alter the overall potential of clot formation and lysis (CL AUC ) suggesting that they might be regarded as biocompatible concerning plasma hemostasis. At potential therapeutic concentrations (constituting IC 50 value for MCF-7 cells) tested polyamine conjugates showed no adverse effects on the membranes of RBCs. The promising antiproliferative activity of representative polyamine conjugates together with their hemocompatibility make them good anticancer drug candidates for further preclinical evaluation.

show abstract

Oxaliplatin-Related Acute Disseminated Intravascular Coagulation Syndrome in a Patient With Metastatic Colon Cancer

Cited by 7 publications

References 22 publications

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion

Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion

Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches

Studies Towards Hemocompatibility of Polyamine Conjugates With Bicyclic Systems

Contact Info

Product

Resources

About